Biomarker to tailor hormone therapy for prostate cancer
Official title: Elucidating a novel molecular biomarker for castration-resistant prostate cancer
Funded at University of Miami School of Medicine · NIH-11377377 · Data updated 2026-11-12
A doctor-and-patient friendly look at a study that tests whether a specific genetic variant can guide when to use intensified hormone therapy for advanced prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | September 26, 2012 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $422,125 |
| NIH project number | 5R01CA172382-14 |
| Project ID | NIH-11377377 on NIH RePORTER |
Who could benefit from this research
✓Could help
Men with advanced prostate cancer who may receive androgen deprivation therapy and its intensified regimens, and who could have the HSD3B1(1245C) germline variant.
✕Less likely to help
Patients without the relevant genetic profile or those not candidates for intensified ADT may derive little to no benefit.
What this research studies
This research investigates a germline genetic variant, HSD3B1(1245C), that may influence how well patients respond to different testosterone-lowering treatments in castration-resistant and castration-sensitive prostate cancer. By combining genetic testing with clinical data, the team aims to understand how this variant affects disease progression and treatment outcomes. The goal is to use this information to personalize therapy, potentially improving survival and reducing unnecessary side effects. The project builds on prior findings and pushes toward applying a biomarker to guide real-world treatment choices for individual patients.
Why it matters
Potential benefit: If successful, patients could receive more tailored therapy based on their genetics, potentially improving outcomes and quality of life.
How similar studies have gone: Previous work has shown a link between HSD3B1(1245C) and resistance to hormone therapy, supporting further validation of this biomarker.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Sharifi, Nima — University of Miami School of Medicine
- Study coordinator: Sharifi, Nima
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.